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Correlates of protectionived from SIV and SHIV have provided the most consistent protection against
challenge with pathogenic viruses, but concerns regarding their long-term safety and efﬁcacy have hampered
their clinical usefulness. We report a longitudinal study in which we evaluated the long-term safety and
efﬁcacy of ΔvpuSHIVPPC, a live virus vaccine derived from SHIVPPC. Macaques were administered two
inoculations of ΔvpuSHIVPPC, three years apart, and followed for eight years. None of the ﬁve vaccinated
macaques developed an AIDS-like disease from the vaccine. At eight years, macaques were challenged with
pathogenic SIV and SHIV. None of the four macaques with detectable cellular-mediated immunity prior to
challenge had detectable viral RNA in the plasma. This study demonstrates that multiple inoculations of a live
vaccine virus can be used safely and can signiﬁcantly extend the efﬁcacy of the vaccine, as compared to a
single inoculation, which is efﬁcacious for approximately three years.
© 2008 Elsevier Inc. All rights reserved.IntroductionThe high capacity of human immunodeﬁciency virus (HIV-1) to
mutate and escape immune responses has been a major obstacle to
developing an effective vaccine against HIV-1. Despite this challenge,
developing a vaccine against HIV-1 is of paramount importance to stem
the global pandemic of HIV-1/AIDS. While numerous strategies for
vaccines have been designed, none have been fully successful. To date,
themost successful vaccines to date in protecting non-humanprimates
against pathogenic SIV and SHIV have been live-attenuated vaccines
based on SIV or SHIV (Whitney and Ruprecht, 2004; Robinson, 2007).
These viruses were obtained by deleting one or more viral genes. The
ﬁrst such vaccinewas SIVmac239 inwhich nefwas deleted. This vaccine
was shown to induce protection of immunized macaques against the
challenge with the highly pathogenic molecularly cloned SIVmac239 or
the uncloned SIVmac251 (Daniel et al., 1992). However, this live-
attenuated vaccine virus was found to be pathogenic in infant
macaques and some adult macaques (Baba et al., 1995, 1999). The
results of these early studies raised a high level of skepticism that a live
virus vaccine against HIV-1 could be developed thatwas safe enough to
use in humans.
Since these early studies, several laboratorieshave investigatedother
live virus vaccines in order to determinewhether an attenuated vaccinel rights reserved.could be developed that is both safe and efﬁcacious (Whitney and
Ruprecht, 2004). Previously, we derived live-attenuated vaccines from
the pathogenic SHIVs to evaluate whether they would protect monkeys
from the highly pathogenic SHIVs and SIVs inprimates. In earlier studies
we described a live-attenuated SHIV-base vaccine ΔvpuΔnefSHIVPPC
(Joag et al., 1998b) and showed it to be safe after serial passage (Mackay
et al., 2002). However, it replicated poorly in vivo and offered little long-
term protection against disease induced by challenge with pathogenic
viruses (Joag et al., 1998b; Mackay et al., 2004a).
To improve the immunogenicity of the SHIV-based vaccine, the
vaccine was redesigned to generate ΔvpuSHIVPPC (Joag et al., 1998b), a
vaccine that replicated much more robustly and was much more
successful in conferring protection against disease caused by
challenge viruses (Joag et al., 1998b; Silverstein et al., 2000; Mackay
et al., 2004a). After challenge with pathogenic virus, vaccinated
animals developed plasma virus levels during the acute phase that
were at least two orders of magnitude lower than unvaccinated
controls (Joag et al., 1998b). Despite the ability of ΔvpuSHIVPPC to
reduce viremia, this vaccine did not prevent viremia and many
vaccinated animals ultimately succumbed to AIDS. A recent study by
Kumar et al. (2008) supported the ﬁnite nature of the protection by
showing that the protection induced ΔvpuSHIVPPC vaccine against
productive infection by a pathogenic virus only lasted approximately
three years after vaccination.
While previous studies established that ΔvpuSHIVPPC has the
potential to be a highly effective vaccine, the long-term safety of this
vaccine had not been evaluated. In addition, it is unknown whether
Fig. 1. Circulating CD4+ and CD8+ T cell levels decline after the ﬁrst inoculation with
ΔvpuSHIVPPC. The absolute numbers of CD4+ (Panel A) and CD8+ (Panel B) T cells were
determined by staining whole blood with anti-CD3, anti-CD4, and anti-CD8. The
numbers shown represent cells per μl blood.
Table 2
Viral RNA in plasma (copies/ml) after second inoculation with ΔvpuSHIVPPCa
RBq RCu RTp RUr RVq
b
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against disease caused by pathogenic virus. In this report we describe
a longitudinal study using adult rhesus macaques immunized twice
with ΔvpuSHIVPPC vaccine to evaluate the safety and efﬁcacy of this
vaccine virus.
Results
Viral load after immunization with ΔvpuSHIVPPC
Five Indian rhesus macaques (RBq5, RCu5, RTp5, RUr5, and RVq5),
were inoculated intradermally with the infectious DNA of the live
vaccine virus ΔvpuSHIVPPC, which contains the X4 env gene from the
HXB2 strain of HIV-1, and the gag, pol, and nef coding sequences from
SIVmac239. This DNA produces replication-competent virus with an
average titer between 104 and 105 TCID50 per ml in the culture
supernatants of transfected HEK-293 T cells (data not shown).
Consistent with previous experiments using ΔvpuSHIVPPC (Joag et al.,
1998a), macaques inoculated with this DNA developed a productive
infection that lasted four to eightweeks, as indicated bymeasuring viral
RNA in plasma (Table 1). In addition, all animals seroconverted and
remained seropositive during the entire study (data not shown).
Circulating CD4+ and CD8+ T cell counts after the ﬁrst inoculation
The levels of circulating CD4+ and CD8+ T cells were calculated
before and after each inoculation with ΔvpuSHIVPPC. After the ﬁrst
inoculation, the number of circulating CD4+ T cells at two weeks post-
inoculation averaged 52%±8.6% the number of CD4+ T cells prior to
inoculation (Fig. 1A). The number of CD4+ T cells returned to at least
90% of pre-inoculation levels within an average of 12±7.1 weeks after
vaccination. The circulating CD8+ T cell levels also declined sharply in
four of ﬁve macaques in the ﬁrst weeks post-inoculation (Fig. 1B). The
four animals that developed a decline in circulating CD8+ T cell levels
had an average of 42%±15% the number of CD8+ T cells prior to
inoculation. Their CD8+ T cell levels returned to within 90% of pre-
inoculation levels within 18±9.5 weeks. Animal RBq did not develop a
decline in CD8+ T cells, suggesting that this animal may have had a
potent immunologic response against the live virus that protected it
from CD8+ T cell loss.
These data indicated that, while ΔvpuSHIVPPC does not induce an
AIDS-like syndrome, the vaccine can cause a transient depletion of
CD4+ and CD8+ T cells. By contrast, the pathogenic form of SHIV
typically causes severe atrophy of the thymus and ablates the CD4+ T
cell compartment in secondary lymphoid tissues within six months of
infection (Joag et al., 1996, 1997a, 1997b).
Viral load and T cell levels following re-immunization with ΔvpuSHIVPPC
Three years after the ﬁrst inoculation (week 161), animals were
inoculatedorallywith1mlof stockΔvpuSHIVPPC virus containing5×105
TCID50 per ml. Similar to the ﬁrst inoculation, the second inoculation
resulted in a transient productive infection followed by an extended
period of latency (Table 2). In four out of the ﬁve animals, the peak
plasma viral RNA levels after the second inoculation was considerablyTable 1
Viral RNA in plasma (copies/ml) after ﬁrst inoculation with ΔvpuSHIVPPCa
RBq RCu RTp RUr RVq
Week 2 16,000 5400 99,000 37,000 73,000
Week 4 2100 1200 ND 80,000 18,000
Week 8 NDb ND ND ND 650
Week 133 ND ND ND ND ND
a Weeks indicate week after ﬁrst inoculation with ΔvpuSHIVPPC.
b ND = none detected.less than that caused by the ﬁrst inoculation, suggesting that these
animals had developed a degree of immunologic protection against
ΔvpuSHIVPPC. Four to eight weeks after the second inoculation, viral
RNAwas undetectable in the plasma, although an occasional resurgence
of viral RNAwasdetected (Table 2). These spikes suggested that the virus
sporadically escaped and produced a low-grade productive infection.
These bursts in viral replication were quickly suppressed as the viral
RNA levels became undetectable at the next measurement.
In four of ﬁve animals, CD4+ T cell counts dropped declined after
the second inoculationwith ΔvpuSHIVPPC (Fig. 2). Except for RBq5, the
average circulating CD4+ T cell levels ﬁve weeks after the second
inoculation (week 166) were 65%±16% of the number prior to re-
inoculation (week 159). Similarly, the number of CD8+ T cells in
animals RCu5, RTp5, RUr5, and RVq5 averaged 56%±8.8% the level
prior to re-infection. RBq5 has no decrease in the number of CD4+ T
cells and only a slight reduction in the number of CD8+ T cells after the
second inoculationwith ΔvpuSHIVPPC, further demonstrating that this
animal had an unusual immunologic response to the vaccine.
Transient depletion of CD8+ T cells
Nearly two years after the second vaccination (week 254), we
sought to determine which of the vaccinated animals still harboredWeek 162 ND 935 2819 ND 612
Week 163 6397 6193 1894 7274 13,377
Week 164 ND ND 2348 400 679
Week 166 983 1263 2361 5276 514
Week 169 ND ND 414 ND ND
Week 173 ND ND ND 1480 ND
Week 182 900 ND ND ND ND
Week 186 ND ND ND ND 480
Week 195 ND ND ND ND ND
Week 251 ND 468 1572 4344 ND
Week 253 ND ND ND ND ND
a Weeks indicate week after ﬁrst inoculation with ΔvpuSHIVPPC.
b ND = none detected.
Table 3
Viral RNA in plasma (copies/ml) after anti-CD8 treatmenta
RBq RCu RTp RUr RVq
Week 254 Anti-CD8 NDb ND ND ND ND
Week 255 ND 9480 42,620 920 85,140
Week 256 ND 548,740 755,620 1,342,640 809,700
Week 257 ND 37,540 18,460 57,320 11,260
Week 258 ND 6860 ND ND 1760
Week 259 ND 4120 860 ND ND
Week 263 ND ND ND ND ND
Week 282 ND ND ND ND ND
Week 361 ND ND ND ND ND
a CD8+ cell immunodepletion led to a robust resurgence in viral load in four of the ﬁve
animals. Animals were injected three times with anti-CD8 during week 254.
b ND = none detected.
Fig. 2. Circulating CD4+ and CD8+ T cell levels after the second inoculation with
ΔvpuSHIVPPC. Macaques were re-inoculated at week 161 and the absolute numbers of
CD4+ (Panel A) and CD8+ (Panel B) T cells were determined as described in the legend to
Fig. 1.
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using a procedure previously shown to be highly effective in reducing
the level of CD8+ Tcells and inducing the re-activation of latent viruses
(Jin et al., 1999; Schmitz et al., 1999; Mackay et al., 2004b). In all ﬁve
animals, the number of CD8+ T cells in the blood decreased to fewer
than 10 cells/µl followed by complete recovery of CD8+ T cells within
four weeks (Fig. 3B). Concomitant with the loss of CD8+ T cells was a
high level of resurgence in the viral mRNA levels in plasma of all
animals except RBq5 (Table 3). These data indicate that all the animals
(except RBq5) still harbored the vaccine virus at the time of anti-CD8Fig. 3. Circulating CD4+ and CD8+ T cell levels after depletion of CD8+ cells. Macaques
were injected intravenously three times with anti-CD8 antibodies during weeks 254
and 255. The absolute numbers of CD4+ (Panel A) and CD8+ (Panel B) T cells were
determined as described in the legend of Fig. 1.treatment. Viral loads returned to undetectable levels upon the
recovery of the CD8+ T cell population.
Two animals (RTp5 and RVq5) had a signiﬁcant loss of CD4+ T cells
following the anti-CD8 treatment, but the levels returned to pre-anti-
CD8 levels within one week (Fig. 3A). The other three animals
developed an increase in CD4+ T cell counts that subsided upon the
return on the CD8+ T cells.
The ﬁve animals were followed for an additional three years after
the anti-CD8 experiment. No viral RNA was detected in the plasma
(Table 3) and the numbers of circulating CD4+ and CD8+ T cells
remained stable during this period (data not shown). At week 400,
blood cells were isolated to determine whether viral DNA could be
detected. Viral DNA could be detected in two of the ﬁve animals (RCu5
and RVq5) (data not shown). These data suggested that the other
animals may have eliminated the vaccine virus or the virus was
present in hematopoietic cells in primary or secondary organs.
Immune responses prior to challenge
Prior to challenge, Gag-speciﬁc, Nef-speciﬁc, and Env-speciﬁc
production of IFNγ by PBMCs was measured by ELISPOT (Fig. 4A) and
antigen-speciﬁc proliferation (ASP) of PBMCs was measured by [3H]
thymidine incorporation (Fig. 4B). The four animals that had
resurgence of virus following anti-CD8 treatment (RCu5, RTp5, RUr5,
and RVq5) had Gag-speciﬁc ELISPOT and ASP responses. In addition,
these four animals had Nef-speciﬁc ELISPOT responses and one animal
(RUr5) had signiﬁcant Nef-speciﬁc ASP. PBMCs from macaque RBq5
did not have any ELISPOT or ASP responses following incubation with
peptides of the three viral proteins, SIV Gag, Nef, or Env. Similarly, the
two unvaccinated control animals (animals 13Z and AL-95) also lacked
ELISPOT and ASP responses against Gag, Nef, or Env.
While the ASP assay showed that PBMCs proliferated in response
to Gag and Nef, this assay did not indicate whether it was the CD4+ or
CD8+ T cells that proliferated. To address this question, we measured
proliferation by examining the dilution of 5-(and -6)-carboxyﬂuor-
escein diacetate, succinimidyl ester (CFSE) by ﬂow cytometry. We
electronically gated on CD4+ or CD8+ T cells and then analyzed
proliferation. Nearly all of the proliferation detected was a result of
proliferation of CD8+ T cells; there was minimal, if any, proliferation of
CD4+ T cells (Fig. 4C).
Next, we investigated whether T cells from vaccinated animals had
a different surface phenotype than T cells from unvaccinated animals.
The percentage of CD3+ PBMCs that were CD4+, CD8+, or CD4+CD8lo
was indistinguishable among the seven animals (Fig. 5A). However,
the CD8+ T cell population in the four animals with Gag-speciﬁc CMI
responses had increased percentages of CD95+ cells, compared to
RBq5 and the unvaccinated controls (88%±9.4% versus 41%±14%,
p=0.010) (Fig. 5A). This suggested that the CD8+ T cells in the four
successfully vaccinated animals had an activated or memory pheno-
type. Because these were outbred animals, it was not possible to
Fig. 4. Vaccinated animals have Gag-speciﬁc and Nef-speciﬁc CMI responses, but not Env-speciﬁc CMI responses, prior to challenge. Panel A. PBMCs were stimulatedwith overlapping
peptides from Gag, Nef, or Env and IFNγ productionwas measured by ELISPOT. The numbers in each bar are the number of IFNγ producing cells/million total PBMCs. Panel B. PBMCs
were stimulated with Gag, Nef, or Env peptides and proliferationwas measured by [3H]thymidine uptake. The stimulation index (SI) was calculated as the number of cpm induced by
peptides divided by the cpm in unstimulated cells. Panel C. PBMCs were loaded with CFSE before stimulation with Gag, Nef, or Env peptides. After four days, cells were harvested
labeled with anti-CD3, anti-CD4, and anti-CD8. The SI for CD3+CD4+ and CD3+CD8+ cells was calculated by dividing the percentage of CFSElo cells in the peptide-stimulated samples by
the percentage of CFSElo cells in the unstimulated.
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persistence of the proliferation and IFNγ production suggested that
the animals developed immunologic memory.We also tested whether sera from these animals developed
neutralizing antibodies against pathogenic SHIVPPC, the parent virus
of the vaccine. The sera were tested nearly eight years after the initial
Fig. 5.Macaques that were protected from challenge had an increase in the percentage of activated/memory CD8+ T cells prior to challenge and an expansion of CD4+CD8lo cells after
challenge. Panel A. Prior to challenge, PBMCs were gated on CD3+ cells and analyzed for CD4 and CD8 expression (upper row). Cells were then gated on CD4+, CD8+, or CD4+CD8lo (DP)
cells and analyzed for CD28 and CD95 expression (lower three rows). Panel B. Eight weeks after challenge, the experiment in Panel A was repeated.
107T.M. Yankee et al. / Virology 383 (2009) 103–111vaccination and prior to challenge. Macaques RBq5, RCu5, and RTp5
had neutralizing antibody titers less than 1:10 while RUr5 had a titer
of 1:80 and RVq5 had a titer of 1:160. These data indicate that only two
of the ﬁve animals developed and sustained detectable neutralizing
antibodies.Protection against challenge
Nearly eight years after the ﬁrst inoculation with ΔvpuSHIVPPC,
ﬁve years after the second inoculation with ΔvpuSHIVPPC, and nearly
three years, after the anti-CD8 treatment (week 404), the ﬁve
Table 4
Viral RNA in plasma (copies/ml) after challengea
RBq RCu RTp RUr RVq 13Z AL-95
Week 404 challenge NDb ND ND ND ND ND ND
Week 405 3,796,200 ND ND ND ND 894,144 818,988
Week 406 11,136 ND ND ND ND 2,109,780 3,777,240
Week 407 86,436 ND ND ND ND 258,108 88,812
Week 408 13,200 ND ND ND ND 338,592 253,608
Week 412 ND ND ND ND ND 1,784,316 140,208
a Four of ﬁve vaccinated animals had no detectable SIV RNA during the eight week
period after challenge.
b ND = none detected.
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challenged with a mixture of the pathogenic viruses SHIVKU2 and
SIVmac239. The four vaccinated animals that had detectable Gag-
speciﬁc CMI responses prior to challenge had no detectable viremia
following challenge with pathogenic virus (Table 4). The two
unvaccinated animals and animal RBq5 developed viral RNA loads
that exceeded 106 viral copies/ml plasma. Whereas RBq5 ultimately
controlled viral replication, the detectable viral mRNA levels persisted
in the unvaccinated controls. These data suggested that RBq5 could
not control the initial replication of the virus, but had an immune
response that protected this animal from chronic viral infections.Fig. 6. Vaccinated animals maintain SIV-speciﬁc CMI after challenge. Panel A. IFNγ productio
proliferation was analyzed by [3H]thymidine uptake and the SI was calculated, as describedThese data suggested that Gag-speciﬁc CMI responses may be
predictive of successful vaccination.
The four protected animals had greatly augmented Gag-speciﬁc
and Nef-speciﬁc ELISPOTand ASP after challenge, compared to prior to
challenge, indicating that infection with pathogenic virus triggered a
robust immune response (Fig. 6). Only two animals (RTp5 and RVq5)
developed Env-speciﬁc ELISPOTand one animal, RUr5, developed Env-
speciﬁc ASP. These data suggested that Gag-speciﬁc and Nef-speciﬁc
immune responses are more essential than Env-speciﬁc immune
responses for the protection of animals against challenge with
pathogenic SIV and SHIV.
Finally, we analyzed the surface phenotype of Tcell populations after
challenge (Fig. 5B). The four vaccinated macaques that resisted
challenge by pathogenic viruses had a four-fold increase in the
percentage of CD3+ PBMC that were CD4+CD8lo, compared to their
respective pre-challenge phenotypes. On average, 2.6%±1.1% of CD3+
PBMCswere CD4+CD8lo prior to challenge and 10%±4.3% of CD3+ PBMCs
were CD4+CD8lo post-challenge (p=0.040, paired t test). A statistically
signiﬁcant increase in the CD4+CD8lo population was not observed
following challenge with pathogenic viruses in macaque RBq5 or the
two control animals. In RBq5 and the control animals, an average of
4.0%±1.5% of CD3+ PBMCs were CD4+CD8lo prior to challenge and 3.3%±
1.1% of CD3+ PBMCswere CD4+CD8lo after challenge (p=0.11). These data
suggested that the increase in CD4+CD8lo cells correlated with immu-
nologic protection.n by PBMCs was calculated as described in the legend to Fig. 4. Panel B. Peptide-speciﬁc
in the legend of Fig. 4.
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The data presented here represent the longest assessment of the
safety and efﬁcacy of a live vaccine virus against SIV in macaques.
Animals were inoculated with ΔvpuSHIVPPC twice in order to
determine if this vaccine strategy could protect animals from
productive infection induced by pathogenic virus. Prior experiments
used a single inoculation of ΔvpuSHIVPPC followed three years later by
challenge with a cocktail of pathogenic viruses (Kumar et al., 2008).
Under these conditions, the vaccine virus was unable to prevent
viremia. However, in the current study, animals were vaccinated, re-
vaccinated three years later, and then challenged ﬁve years after the
second inoculation. Four of ﬁve animals were aviremic following
infection with challenge viruses. These data demonstrate that multi-
ple inoculations with a live virus vaccine can extend the efﬁcacy of the
vaccine.
Despite transient declines in circulating CD4+ and CD8+ T cell
levels, no sustained loss of CD4+ or CD8+ T cells was observed in any of
the ﬁve vaccinated animals, indicating that ΔvpuSHIVPPC was safe for
use in the context of repeated inoculations over time. A possible
explanation for these transient decreases in the number of circulating
T cells is that the virus may infect and kill thymocytes. When
replication of ΔvpuSHIVPPC is controlled, the thymus may be restored
and T cell counts recover. Alternatively, the depletion of circulating T
cells could be attributed to re-localization of cells from the blood into
lymphoid tissues. Further studies are required to determine the
mechanism.
Previous studies demonstrated that the vaccine virus must persist
in order for protection against disease induced by pathogenic virus to
be sustained (Kumar et al., 2008). In the current study, we treated
macaques with anti-CD8 antibodies to transiently deplete the animals
of CD8+ T cells to determine if a resurgence in viremia would occur
from undetectable reservoirs of the vaccine virus (Table 3). While this
treatment demonstrated that four of ﬁve vaccinated animals still
harbored virus, it also led to a third bolus of vaccine virus. This extra
bolus may have boosted the immune responses against Gag and Nef,
adding to the efﬁcacy of the vaccine. The animals that had three
boluses of viral replication did not develop high viral loads and AIDS,
despite having an average of 34-fold increase in viral burdens after the
anti-CD8 treatment than after either immunization. These data clearly
demonstrate that the virus remained viable, but had not reverted to a
pathogenic phenotype.
A striking feature of the protective immunity observed in this
study was the complete lack of viremia in successfully vaccinated
animals (Table 4). This remarkable suppression of viral replication
was likely due to Gag-speciﬁc and Nef-speciﬁc CD8+ T cells that
could recognize and become activated by MHC class I-expressing
cells that presented Gag or Nef peptides because no Env-speciﬁc
immune responses could be detected in most animals. The
importance of Gag-speciﬁc immune responses was highlighted in a
recent paper by Kiepela et al. (2007), who showed in HIV-infected
individuals that Gag-speciﬁc immune responses were associated
with lower levels of viremia and Env-speciﬁc responses were
associated with higher levels of viremia. In addition, it was recently
reported that the Gag liberated during the virus-uncoating stage can
be processed and presented on MHC class I prior to viral integration
(Sacha et al., 2007). In the case of an intravenous injection of
challenge virus, it is likely that virus infected the macrophages in
the blood and spleen and then Gag-speciﬁc CD8+ T cells targeted
and killed the infected cells before the virus could complete its life
cycle.
Of note, little or no Env-speciﬁc cellular-mediated immune
responses were detected prior to challenge in any of the animals
and only two animals had detectable anti-SHIVPPC neutralizing
antibody titers prior to challenge. In addition, the animals were
vaccinated with a derivative of SHIV that contains a macaque-adaptedHXB2 envelope glycoprotein, which is CXCR4-tropic. The animals
were challenged with a mixture of CXCR4-tropic SHIVKU2 and CCR5-
tropic SIVmac239. If there were undetectable Env-speciﬁc immune
responses in the vaccinated animals, these responses would likely
be directed against the challenge SHIV, not SIV. However, our data
demonstrated that ΔvpuSHIVPPC protected against productive
infection by both SHIVKU2 and SIVmac239, suggesting that Env-
speciﬁc immune responses were not critical for immunological
protection of the challenge viruses. This observation is highly
signiﬁcant for vaccine design because Env is not well conserved
across HIV-1 strains and subtypes while Gag is more conserved.
Thus, it is likely that a single vaccine could be effective against
multiple strains of HIV-1 and perhaps multiple subtypes of the
virus.
It is unlikely that the mechanism of protection conferred by
ΔvpuSHIVPPC is viral interference becauseΔvpuSHIVPPC and SIVmac239
have different tropisms. ΔvpuSHIVPPC targets CXCR4-expressing CD4+
T cells, which are primarily naïve peripheral T cells and T cell
precursors in the thymus. SIVmac239 targets CCR5-expressing cells,
which are primarily memory T cells. Another reason that viral
interference is unlikely is that, at the time of challenge, there was
no detectable vaccine virus in the plasma. It is difﬁcult to conceive that
an undetectable viral load could interfere with a high intravenous
dose of challenge virus.
Macaque RBq5 was the outlier in this study. This animal did not
develop a resurgence of virus after treatment with the anti-CD8
antibodies (Table 3), suggesting that the animal had eliminated the
vaccine virus. The lack of CMI responses against Gag and Nef
together with failure of the vaccine virus to persist supported our
previous work showing that maintenance of vaccine-induced CMI
responses required persistence of the virus (Joag et al., 1998b;
Silverstein et al., 2000; Mackay et al., 2004a). More importantly,
however, the data from RBq5 reinforced the conclusion from the
present study that CMI responses against Gag and Nef correlated
with protection from productive infection by the challenge virus.
The fact that this animal developed control of the challenge virus,
similar to the manner in which it controlled the vaccine virus,
suggested that it had mounted a strong innate immune response
that did not develop into an adaptive immune response. This
conclusion was also supported by the fact that RBq5 did not develop
the transient loss of T cells following inoculation with the vaccine
see in the other animals.
Coinciding with control of replication of the challenge virus, CD4+
CD8lo T cells underwent substantial expansion in the successfully
vaccinated animals (Fig. 2). CD4+CD8lo T cells were ﬁrst described in
humans by Blue et al. (1985) and have since been found in healthy
individuals as well as in patients with viral infections, tumors, and
autoimmune diseases. In healthy individuals, the majority of CD4+
CD8lo T cells have amemory phenotype and can be readily activated by
virally infected cells in vitro (Nascimbeni et al., 2004; Pahar et al.,
2006). This has led to the speculation that peripheral CD4+CD8lo T cells
are terminally differentiated memory T cells. In further support of this
model, CD4+CD8lo T cells have been shown to be expanded
preferentially in an individual infected with HIV for eight years
(Weiss et al., 1998). CD4+CD8lo T cells are a target for SIV infection in
macaques (Akari et al., 1999). The expansion of this population of cells
in the animals resisting productive infection by pathogenic virus
suggested that these cells are an important component of the immune
response needed to control viral replication.
In conclusion, the results presented here describe a longitudinal
study in which macaques were inoculated twice over the course of an
eight-year study. Whereas previous studies using a single inoculation
demonstrated that ΔvpuSHIVPPC could not protect animals from
productive infection by a pathogenic virus beyond three years, this
study shows that a second inoculation extended the duration of
protection beyond eight years.
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Animals and vaccination
Indian rhesusmacaqueswere housed individually in the Laboratory
Animal Resources building of the University of Kansas Medical Center
(Kansas City, KS) under conditions approved by the Association for the
Assessment andAccreditation of Laboratory Animal Care. These studies
were begunwhen the animalswereﬁveyears old. All experimentswere
performed in compliance with the University of Kansas Medical Center
Institutional Animal Care and Use Committee.
Infectious DNA of ΔvpuSHIVKU1 was prepared as described earlier
(Joag et al., 1998a). A virus stock was prepared from this DNA by
transfecting CEM174 cells with the DNA followed by harvest of
supernatant ﬂuid several days later. Animals were inoculated
intradermally with 200 μg of the infectious DNA suspended in 2 ml
of PBS. The animals were injected at four sites with 0.5 ml of the DNA
suspension. Three years later, animals were revaccinated orally with
the vaccine virus. Each animal was tranquilized and 1 ml of the viral
suspension was placed at the back of the mouth using a 1 ml syringe.
Stocks of SIVmac239 and SHIVKU2 were prepared by inoculating
CD8-depleted PBMCs from a rhesus macaque. The supernatant ﬂuid
from this culturewas collected, aliquoted, and frozen at −80 °C, similar
to the vaccine virus. Infectivity of both viruses was assessed in CEM174
cells and showed a titer of approximately 105 TCID/ml.
Processing of blood samples
Peripheral venous blood collected in EDTA was centrifuged to
separate plasma and buffy coats. Plasmawas frozen for determination
of plasma viral RNA concentrations. PBMC were separated from buffy
coats by centrifugation through Ficoll-Paque density gradients and
portions used for virus isolation, ﬂow cytometry, antigen-speciﬁc
proliferation (ASP), and ELISPOT assays.
Determining plasma viral RNA using quantitative real-time RT-PCR analysis
Plasma viral RNA loads were measured in RNA extracted from
800–100 μl of EDTA anticoagulated plasma samples as previously
described (Mackay et al., 2002, 2004a). Brieﬂy, RNA samples were
subjected to real-time RT-PCR using gag speciﬁc primers (forward —
GCAGAGGAGGAAATTACCCAGTAC, reverse — CAATTTTACCCAGGCATT-
TAATGTT), 5′-FAM- and 3′-TAMRA-labeled TaqMan probe (TGTCCA-
CCTGCCATTAAGCCCGA), and the Taqman Universal PCR Mastermix
(Applied Biosystems) in duplicate reactions in the ABI PRISM 7700
Sequence Detection System (Hofmann-Lehmann et al., 2000). These
primers and probes detect all SHIVs and SIVs in this study. Viral RNA
copy numbers were calculated per milliliter of plasma. The minimal
level of detection was 360 copies/ml.
Flow cytometry and determination of CD4/CD8 levels
Anti-CD3-FITC, anti-CD4-PE, anti-CD8-APC-Cy7, anti-CD28-APC,
and anti-CD95-PE were purchased from BD Bioscience, San Jose, CA.
Flow cytometry studies were performed using a BD LSR II (BD
Immunocytometry Systems, San Jose, CA). Data were analyzed using
BD FACSDiva software (BD Biosciences, San Jose, CA). The absolute
numbers of CD4+ and CD8+ T cells were calculated by multiplying the
percentage of CD4+CD3+ and CD8+CD3+ cells by the lymphocytes/μl
from a complete blood count.
Antigen-speciﬁc proliferation (ASP) assays
The ASP assays were performed as previously described (Mackay
et al., 2004a). Brieﬂy, triplicate cultures of PBMC were incubated with
overlapping peptides derived from Gag, Nef, or Env for four days at37 °C. The peptides were 15-mers based on the sequence of the
SIVmac239 and spanned the entire length of the proteins. Peptides
were kindly provided by the National Institutes of Health AIDS
Research and Reference Reagent Program (McKesson Bio-Services,
Germantown, MD). [3H]Thymidine was added to the culture 18–24 h
before harvesting. [3H]Thymidine incorporation was measured by
liquid scintillation counting (Packard Instrument, Meriden, CT).
Stimulation indices (SI) were calculated as mean cpm, divided by
the mean cpm in control wells. SI values greater than three were
considered signiﬁcant because SIs greater than two were never
obtained with PBMCs from non-immunized animals.
ELISPOT assays
ELSIPOT assays were performed as described previously (Mackay
et al., 2004b). Brieﬂy, IFNγ production was measured by incubating
PBMC with the same peptides used for ASP analyses. Millipore
multiscreen Immobilon-P opaque hydrophobic high-protein binding
96-well plates (0.45 μm; Billerica, MA) were coated with anti-monkey
IFNγ (Mabtech, Stockholm, Sweden). Cells were incubated with media
alone, media containing peptides, or media containing Con A. After
incubation and washing, Vectastain AB kit (Vector Laboratories,
Burlingame, CA) was added. Color development was performed
using Nova-Red. Spots were counted with a stereomicroscope and
reported as number of sports/106 PBMC.
CD8+ T cell depletion
On day 0 of treatment, animals were given 10 mg/kg anti-CD8
antibodies subcutaneously. On days 3 and 7, animals were injected
intravenously with 5 mg/kg anti-CD8 antibodies. The anti-CD8
antibodies were kindly provided by Dr. Keith Reimann, Beth Israel
Deaconess Medical Center, Harvard Medical School. Blood samples
were obtained at the indicated time points for analysis.
Neutralizing antibody assay
Two-fold dilutions of sera were mixed with 100 TCID50 and
CEMX174 cells. Virus-seramixtures were incubated at 37 °C for 30min
and then inoculated into respective indicator cell cultures. Inoculated
cells were examined for development of fusion cytopathic effects
everyday for one week.
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